Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962049 | 1.00 | KIF11 (0.56) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL9962123 | 1.00 | KIF11 (0.56) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL30757605 | 1.00 | KIF11 (0.56) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL8403050 | 0.96 | ABCG2 (0.57) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL8403288 | 0.94 | TP53 (0.61) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL11912892 | 0.94 | TP53 (0.60) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL8403286 | 0.93 | TP53 (0.54) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL16299549 | 0.92 | KIF11 (0.51) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| Emvododstat SCHEMBL9962251 | 0.91 | TP53 (0.62) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL764777 | 0.91 | TP53 (0.55) | KIF11TP53MAPTSMN1; SMN2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858361-B1 | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR EFFECT ENHANCER USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE | FUJIFILM CORP (JP) | 2025-10-08 | — | — | EP | claimed |
| US-11890296-B2 | Anti-tumor agent containing cytarabine, anti- tumor effect enhancing agent which is used in combination with cytarabine, anti-tumor kit, and anti-tumor agent which is used in combination with cytarabine | FUJIFILM CORPORATION (JP) | 2024-02-06 | — | — | US | claimed |
| EP-3858361-A1 | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR EFFECT ENHANCER USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE | FUJIFILM Corporation (JP) | 2021-08-04 | — | — | EP | claimed |
| US-20210213040-A1 | ANTI-TUMOR AGENT CONTAINING CYTARABINE, ANTI-TUMOR EFFECT ENHANCING AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE, ANTI-TUMOR KIT, AND ANTI-TUMOR AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE | FUJIFILM CORPORATION (JP) | 2021-07-15 | — | — | US | claimed |
| EP-3858361-B1 | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR EFFECT ENHANCER USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE | FUJIFILM CORP (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-11890296-B2 | Anti-tumor agent containing cytarabine, anti- tumor effect enhancing agent which is used in combination with cytarabine, anti-tumor kit, and anti-tumor agent which is used in combination with cytarabine | FUJIFILM CORPORATION (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3858361-A1 | ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR EFFECT ENHANCER USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE | FUJIFILM Corporation (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-20210213040-A1 | ANTI-TUMOR AGENT CONTAINING CYTARABINE, ANTI-TUMOR EFFECT ENHANCING AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE, ANTI-TUMOR KIT, AND ANTI-TUMOR AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE | FUJIFILM CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703726-B2 | Methods for treating prostate conditions | PTC THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20090209521-A9 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127715-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064683-A1 | Inhibition of VEGF Translation | PTC THERAPEUTICS, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | PCT THERAPEUTICS, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064683-A1 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | KIF11 2929/4885TP53 854/4885MAPT 4518/4885 |
| US-11890296-B2 | Anti-tumor agent containing cytarabine, anti- tumor effect enhancing agent which is used in combination with cytarabine, anti-tumor kit, and anti-tumor agent which is used in combination with cytarabine | DHODH, DPYD, DCTD | KIF11 2120/4885TP53 307/4885MAPT 4750/4885 |
| US-20090209521-A9 | Inhibition of VEGF Translation | EIF4E, EIF4EBP1, VEGFA | KIF11 2929/4885TP53 854/4885MAPT 4518/4885 |
| US-20130171103-A1 | METHODS FOR TREATING VIRAL CONDITIONS | EIF2AK2, POLRMT, POLM | KIF11 2855/4885TP53 156/4885MAPT 2440/4885 |
| US-20210213040-A1 | ANTI-TUMOR AGENT CONTAINING CYTARABINE, ANTI-TUMOR EFFECT ENHANCING AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE, ANTI-TUMOR KIT, AND ANTI-TUMOR AGENT WHICH IS USED IN COMBINATION WITH CYTARABINE | DHODH, DPYD, DCTD | KIF11 2120/4885TP53 307/4885MAPT 4750/4885 |
| US-20070281962-A2 | Administering 1,2,3,6-tetrasubstituted pyrido[3,4-b]indoles to inhibit the 5'-untranslated region-dependent translation; anticarcinogenic agents; retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, macular degeneration | VEGFA, FLT4, MIF | KIF11 3352/4885TP53 448/4885MAPT 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.